Genomic analysis of human cancers indicates that the loss or mutation of core autophagy related genes, (ATG) is uncommon, whereas oncogenic events that activate autophagy and lysosomal biogenesis have been identified. Several studies have demonstrated that autophagy plays a wide variety of physiological and pathophysiological roles in cells: a cellular process that maintains the homeostasis of the normal cell, while self-defects can lead to a lawsuit to accelerate tumorigenesis and developing diseases, such as cancer. Depending on different contexts, autophagy dysfunctions may play a role: neutral, tumor-suppressive, or tumor-promoting. The process of autophagy may function in tumor suppression by mitigating metabolic stress and, in concert with apoptosis, by preventing tumor cell death by necrosis. In this case, optimal combination of autophagy inhibition (CQ, HCQ) with other conventional therapies - chemo or radiotherapy in a variety of tumor types in different phases can be successful approaches for improve the effect of anticancer therapies. This review examines recent insights of the molecular mechanism of autophagy and the potential roles of autophagy in cell death, cancer development, overview of the most recent therapeutic strategies involving autophagy modulators in cancer prevention and therapeutic opportunities.
Apoptosis is an energy-related process, which occurs in the absence of adenosine-triphosphate (ATP). A strong correlation was observed between the concentration of ATP of T lymphocytes from patients with malignant diseases and the ATP concentration of B lymphocytes from patients with chronic lymphocytic leukemia. Further studies are necessary using fluorescence in situ hybridization (FISH) technology to detect patients with high concentrations of ATP and the mutations, translocations, or deletions of the p53 gene, which is located on chromosome 17.
: Breast cancer affects more than one million patients annually in the world and is a leading cause of mortality. Histological type, grade, tumor size, lymph node involvement, and estrogen receptor and HER-2 receptor status, all influence prognosis and the probability of response to systemic therapies. Purpose: Aim of this work was to emphasize possible links between alterations of the P-53 gene, together with its protein, in the pathological features of breast cancer, resistant to a conventional therapy. Method: New genetic technologies were investigated to promote a stronger anti-oncogene response, using both RNA-based p53 vaccines and the likelihood of response to specific oncological therapies. Results: Studies have shown that mutant P-53 gene had a strongly unfavorable prognostic factor for relapse-free survival and overall survival only in a triple-negative group in patients treated with adjuvant anthracycline-containing chemotherapy. The adjuvanted vaccine induced the type T1 cells helper response in most patients. However, the response has not yet been shown to be strong enough to be beneficial as monotherapy and most patients have had T-helper cells that have failed to produce effective cytokines to kill cancer cells. The results of these studies justified attempts to discover and apply the new vaccines to cancer patients using p53-derived peptides. Conclusions: Conditions of the mutant P-53 gene or deletion of 17p chromosome were an unfavorable prognostic factor for the survival of patients, treated with adjuvant chemotherapy, in the groups with triple-negative forms of BC.